Model & Strategy
D-Rev serves the population of nearly 4 billion people who live on less than $4/day. D-Rev aims to improve the lives of the world’s poorest by designing, developing and distributing radically affordable world-class medical products at two-thirds of the cost. In doing this, D-Rev directly improves the health and productivity of the poor and spurs competitors to introduce more affordable, higher performing products— solving the problem of access to and availability of medical care products at a systems level, on a global scale.
D-Rev currently has two products in the market: 1) ReMotion Knee – a high-performing knee joint for developing world amputees – and 2) Brilliance – a jaundice treatment device at an affordable price. To meet full market demand, D-Rev licensed both these products to for-profit distributors in developing countries. D-Rev’s value add is embedded in both its customer driven search for product solutions and in its commitment to ensuring successful distribution of the products it designs.
For its work to bring a design ethic to third-world healthcare, D-Rev was named one of Fast Company’s World’s Most Innovative Companies and awarded as a Tech Laureate at the 2013 Tech Awards.
Krista Donaldson, PhD, has driven innovation in product design, engineering and international development for more than 15 years. As D-Rev’s CEO, Krista spearheaded the release of Brilliance, a revolutionary technology treating neonatal jaundice, and the release of ReMotion prosthetic knee. Her leadership has won Krista acclaim as one of Fast Company’s Co.Design 50 Designers Shaping the Future, a TED speaker and a World Economic Forum Technology Pioneer.
Prior to D-Rev, Krista was a Diplomacy Fellow in the U.S. Department of State’s American Association for the Advancement of Science (AAAS), where she guided economic policy and the reconstruction of Iraq’s electricity sector, earning her recognition for her work’s impact on bilateral relations. From 1998 to 2001, she worked with KickStart International (formerly ApproTEC) in Nairobi, Kenya as a design engineer and researcher, and with the product design firm IDEO.
In 2019, D-Rev surpassed half a million patients treated, of which they estimate over 85% would likely have not otherwise received effective treatment.
With Brilliance, D-Rev’s newborn jaundice product, 370,500 babies have been treated, of which over 90% would likely have not otherwise received effective treatment; 4,783 units have been sold in 61 countries. D-Rev only reports impact where there are confirmed installations.
The ReMotion Knee, D-Rev’s amputee mobility product, has been sold in 30 countries to 531 amputees, of which over 300 would likely have not otherwise been fit.
D-Rev has been recognized by ImpactMatters for its rigor in measuring impact. As a result, Peter Singer, who has promoted “Effective altruism,” has called D-Rev one of the world’s most highly effective charities.
Why an $80 Artificial Knee Outruns a $1,000 VersionKrista Donaldson, founder and CEO of D-Rev, recently took the stage at Fortune’s Brainstorm Health conference to discuss how D-Rev’s revolutionary $80 artificial knee is making mobility possible…Nov 2016
Life-Changing, Low-Cost Artificial Knee Is On The MarketIn low-income countries where injuries from accidents or war often lead to amputation, most people haven’t been able to afford a quality prosthetic in the…Dec 2015
Listening for Disruption: Blue Lights and New KneesIn 2012, D-Rev released its first product, Brilliance, a phototherapy lamp to treat neonatal jaundice that sold for $500 — rather than the typical price…Dec 2015
13 Badass Moms Who Are Saving the WorldTalk about a game changer: Krista designs and brings medical technologies to low income populations—and is saving lives in the process. As CEO of the…Sep 2015